NFKB1 and metabolic dysfunction-associated steatohepatitis: On the other hand, pharmacological inhibition of FABP4 by BMS309403 alleviates both acute liver injury and NASH, potentially through JNK and nuclear factor κB (NF-κB) inhibition [62].